For example, inhibition of ITK in T cells appears to promote beneficial Th1 immunity, and both BTK-dependent and -independent effects appear to contribute to enhanced T cell numbers and function in CLL patients [58, 59]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.